Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High-dose posaconazole for azole-resistant aspergillosis and other difficult-to-treat mould infections.

Mycoses - 1 Feb 2020

Schauwvlieghe Alexander F A D, Buil Jochem B, Verweij Paul E, Hoek Rogier A S, Cornelissen Jan J, Blijlevens Nicole M A, Henriet Stefanie S V, Rijnders Bart J A, Brüggemann Roger J M

Abstract excerpt

BACKGROUND: Oral follow-up therapy is problematic in moulds with reduced azole-susceptibility, such as azole-resistant Aspergillus fumigatus infection. Currently, only intravenous liposomal amphotericin B (L-AmB) is advocated by guidelines for the treatment of azole-resistant aspergillosis infections. Preclinical research indicates that high-dose posaconazole (HD-POS) might be a feasible option provided that high...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antifungal Agents
Share to Aspergillosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Azoles

Share to Cytochrome P-450 Enzyme System

Share to Drug Resistance, Fungal

Share to Likelihood Functions

Share to Probability

Share to Triazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 31660650
DOI: 10.1111/myc.13028
PMCID: PMC7003872

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

High-dose posaconazole for azole-resistant aspergillosis and other difficult-to-treat mould infections.PMID 31660650Read ↗

The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside.Semantic proximity Read ↗

A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).Semantic proximity Read ↗

Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults.Semantic proximity Read ↗

Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.Semantic proximity Read ↗

Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients.Semantic proximity Read ↗

Bioactivity of new AmB-PMA nanoparticle in prophylaxis and treatment of transplant-related invasive aspergillosisSemantic proximity Read ↗

Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis.Semantic proximity Read ↗

Highly Variable Plasma Concentrations of Voriconazole in Pediatric Hematopoietic Stem Cell Transplantation PatientsSemantic proximity Read ↗

Aspergillus nidulans is frequently resistant to amphotericin BSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.